News

Reduction in COVID-19 Virus Exposure May Benefit Patients, Doctors and Nurses

DUBLIN, OHIO—August 11, 2020—N8 Medical, LLC, a privately held biotechnology company, today announced that its CeraShield™ coated endotracheal tubes significantly reduced the growth of COVID-19 virus in recent testing. The testing shows statistically significant reduction in the growth of the COVID-19 virus on the tube surface in 60 minutes. Ordinary uncoated endotracheal tubes either allowed increased virus growth or had no inhibitory effect.

“Recent COVID-19 research has shown that the virus is able to adhere to plastic surfaces and is also able to be aerosolized and inhaled by people in close proximity, including doctors and nurses” says Ronald Bracken, President and Chief Operating Officer of N8. Mr. Bracken added “Most endotracheal tubes are made of plastic. COVID-19 patients who become mechanically ventilated will require use of one of these plastic tubes to connect to the mechanical ventilator.”
Ordinary endotracheal tubes lack any antifouling protection.  Within hours, these tubes become breeding grounds for biofilms, pathogenic bacteria, fungi and viruses. This often leads to deadly secondary infections that can be multidrug resistant, and other complications.
Dr. Michael Niederman, a leading expert in respiratory infections and a member of N8 Medical’s Scientific Advisory Board stated “Anything that can significantly reduce the presence of pathogens on the surface of an endotracheal tube is a welcome advance that has the potential to reduce a patient’s length of stay, reduce antibiotic and drug use and improve patient’s outcomes.  I look forward to the results of clinical studies to evaluate the magnitude of the potential benefit of the CeraShield™ endotracheal tube in COVID-19 patients.”

N8 Medical has previously completed first-in-human clinical trials in non-COVID, mechanically ventilated patients with no adverse effects.  Those clinical studies have shown that the CeraShield™ endotracheal tubes were able to completely prevent pathogenic bacterial and fungal biofilm growth of tube surfaces.

A leading market research firm recently awarded N8 Medical’s CeraShield™ endotracheal tube “Product Innovation of the Year” award for its CeraShield™ technology platform for prevention of hospital-acquired infections. FDA has designated the CeraShield™ endotracheal tube as a “breakthrough device.”

N8 Medical News

Here you will find the latest information, including: press releases, events and presentations and blog posts.

Newsletter Sign-up

Interested in hearing whats new with N8 Medical? Sign-up to join our newsletter.

Email Address

Sign up

Recent Posts

N8 Medical and USAMRIID Enter CRADA to Test CSA Compounds Against Anthrax and other Biodefense Pathogens

Lets Get in Touch!

  • info@n8medical.com
  • N8 Medical, LLC1090 Center DrivePark City, UT 84098
Follow now
Linkedin
[gravityform id="3" title="true"]

N8 Medical, Inc. (N8 Medical) is a clinical-stage medical device company focused on commercializing medical devices that incorporate a novel class of active compounds called ceragenins.The subsidiaries for N8 Medical Inc are N8 Medical, LLC for Medical Device Development and Kinnear Pharmaceuticals, LLC for drug development.

Useful Links

Our Company